Immuno-Oncology | Specialty

CDK4/6 Inhibition in Hormone Receptor-Positive mBC

January 22nd 2020

Strategies for Hormone Receptor-Positive Metastatic BC

January 22nd 2020

HER2+ Breast Cancer: Future Treatment Landscape

January 11th 2020

Practical Advice on Treating HER2+ Metastatic Breast Cancer

January 11th 2020

Targeting HER2 Outside of Breast Cancer

January 11th 2020

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC

January 11th 2020

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020

HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020

HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates

January 11th 2020

Unmet Needs in the Management of HER2+ mBC

January 11th 2020

Treatment Strategies for Relapsed/Refractory HER2+ mBC

January 11th 2020

HER2+ BC: Selection and Management of Neoadjuvant Therapy

January 11th 2020

Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020